143 articles
Stapokibart
Stapokibart (Kangyueda, 康悦达; CM310) is a humanized IgG4 anti-IL-4Rα monoclonal antibody by KeyMed Biosciences, first approved in China in 2024 for moderate-to-severe atopic dermatitis, later CRSwNP and seasonal allergic rhinitis.
Tabalumab
Tabalumab (LY2127399) is Eli Lilly's human IgG4 monoclonal antibody neutralizing soluble and membrane-bound BAFF. Its Phase 3 rheumatoid arthritis and lupus (ILLUMINATE) programs failed on efficacy, and development stopped in October 2014.
Talquetamab
Talquetamab (Talvey, talquetamab-tgvs), Janssen Biotech's bispecific GPRC5D x CD3 T-cell engager antibody for relapsed/refractory multiple myeloma; FDA accelerated approval August 2023, boxed warning CRS and ICANS, Tecvayli-Talvey REMS.
Tambotatug pelitecan
YL201 (Tam-Peli, tambotatug pelitecan, RG6919) is a B7-H3-targeting antibody-drug conjugate from MediLink Therapeutics' TMALIN platform, DAR 8, licensed to Roche in 2026 for $570 million upfront, in phase 3 for SCLC and NPC.
Tecotabart vedotin
Tecotabart vedotin (LM-302, TPX-4589) is LaNova Medicines' anti-CLDN18.2 antibody-drug conjugate carrying MMAE via a cleavable linker, in priority review in China for CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma after two prior lines.
Telazorlimab
Telazorlimab (GBR 830, ISB 830) is a humanized anti-OX40 IgG1 monoclonal antibody for atopic dermatitis; completed phase 2b (EASI −54.4% vs −34.2% placebo), licensed to Astria Therapeutics 2023, now under BioCryst after its 2026 Astria acquisition.
Telikibart
Telikibart (GR1802, 泰利奇拜单抗) is Genrix Bio's fully human anti-IL-4Rα IgG1κ monoclonal antibody for atopic dermatitis, CRSwNP, urticaria, rhinitis, and asthma; Phase 3 in China, NDA accepted by NMPA in 2025.
Telpegfilgrastim
Telpegfilgrastim (拓培非格司亭) is a long-acting PEGylated G-CSF developed by Xiamen Amoytop Biotech and approved in China in June 2023 to reduce febrile neutropenia in chemotherapy patients.
Teprasiran
Teprasiran (QPI-1002, I5NP) is a naked p53-targeting siRNA from Quark Pharmaceuticals, licensed to Novartis, for preventing acute kidney injury after cardiac surgery and delayed graft function after kidney transplant; positive phase 2 but terminated phase 3, not approved.
Teprotumumab
Teprotumumab (Tepezza, teprotumumab-trbw), fully human anti-IGF-1R monoclonal antibody; first FDA-approved drug (2020) for thyroid eye disease, given as 8 IV infusions; improves proptosis and diplopia, risks hyperglycemia and hearing impairment.
TQH2722 (IL-4Rα antibody)
TQH2722 (BSI-045A) is a humanized IgG4 anti-IL-4Rα monoclonal antibody by Chia Tai Tianqing and Biotheus, blocking IL-4/IL-13 signaling; Phase III in atopic dermatitis with CDE NDA accepted in 2026.
UB-221
UB-221 (CUE-221, Ascendant-221) is a humanized anti-IgE IgG1 monoclonal antibody, humanized from mouse clone 8D6, that binds IgE Cε3, neutralizes free IgE, and uniquely spares CD23-mediated IgE downregulation; in Phase 2 CSU trials it beat placebo and outperformed omalizumab.
Ublituximab
Ublituximab (Briumvi) is a glycoengineered chimeric anti-CD20 IgG1 monoclonal antibody by TG Therapeutics for relapsing multiple sclerosis, approved in the US (2022), EU (2023), and Australia (2025), given as one-hour infusions every 24 weeks.
Visilizumab
Visilizumab (Nuvion, HuM291) was a humanized anti-CD3 IgG2 monoclonal antibody for steroid-refractory ulcerative colitis and Crohn's disease; development was terminated in 2007 after insufficient efficacy and inferior safety versus intravenous steroids.
Volanesorsen
Volanesorsen (ISIS 304801, Waylivra) is a 2'-MOE antisense oligonucleotide against apoC-III mRNA, EU-approved conditionally in 2019 for familial chylomicronaemia syndrome; not FDA-approved, with thrombocytopenia and injection site reactions as main risks.
Voxinkibart (伏欣奇拜单抗) injection
Voxinkibart (伏欣奇拜单抗), also known as firsekibart or Genakumab, is a monoclonal antibody drug for acute gouty arthritis developed by GenSci and approved in China in 2025.
Vunakizumab
Vunakizumab (SHR-1314, 安达静) is a humanized IgG1 anti-IL-17A monoclonal antibody by Hengrui's Suzhou Suncadia, approved in China (2024) for plaque psoriasis and (2025) for ankylosing spondylitis.
Xeligekimab (GR1501)
Xeligekimab (GR1501, 赛立奇单抗, brand Jinlixi) is a fully human IgG4 monoclonal antibody neutralizing IL-17A, developed by Chongqing Genrix Biopharmaceutical and approved in China (2024 psoriasis, 2025 ankylosing spondylitis), the first domestic anti-IL-17A drug.
YL211
YL211 (RG6648) is a c-Met-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload, DAR 8, built on MediLink's TMALIN platform; licensed to Roche in January 2024 for up to nearly $1 billion and in Phase I trials for advanced solid tumors.
Zenocutuzumab
Zenocutuzumab-zbco (Bizengri, MCLA-128) is a bispecific HER2/HER3 antibody by Merus and Partner Therapeutics for NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma; FDA-approved 2024 and 2026.
Zevorcabtagene autoleucel (zevor-cel, CT053)
Zevorcabtagene autoleucel (zevor-cel, CT053; 泽沃基奥仑赛注射液, brand 赛恺泽) is CARsgen's fully human BCMA-directed autologous CAR T-cell therapy, conditionally approved in China February 2024 for relapsed/refractory multiple myeloma after three prior lines, with fixed 1.5×10^8 cell dosing.
Zigakibart
Zigakibart (BION-1301, FUB523) is a Novartis humanized IgG4 monoclonal antibody blocking APRIL, in phase 3 (BEYOND, NCT05852938) for IgA nephropathy, with phase 1/2 data showing 60% proteinuria reduction and eGFR stabilization.
Zuberitamab
Zuberitamab (HS006, Anruoxi) is a Chinese class 1 chimeric anti-CD20 monoclonal antibody by BioRay, approved May 2023 with CHOP for CD20-positive DLBCL; phase 3 showed non-inferior ORR and higher CR versus rituximab.